HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jan. 20, 2005--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) and its affiliates and subsidiaries ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for
HAWTHORNE, N.Y., Dec. 27, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application ("ANDA") for Hydrocortisone Butyrate Ointment, 0.1%.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Dec. 23, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) and its affiliates and subsidiaries ("Taro") announced today that it will supply Agis Industries (1983) Ltd. ("Agis") and its subsidiary, Clay Park Labs, Inc.
HAWTHORNE, N.Y., Dec. 16, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Dec. 6, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received tentative approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug
HAWTHORNE, N.Y., Dec. 6, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application
HAWTHORNE, N.Y., Nov. 22, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. ("Taro," "the Company," (Nasdaq:TARO)) today reported that it has received an "A+" rating from Maalot, the Israeli affiliate of Standard & Poor's, based on the rating standard employed in Israel, for the issuance of
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 28, 2004--Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Nasdaq: TARO) today reported results for the Company's third quarter and the nine-month period ended September 30, 2004. Third Quarter 2004 Results Taro's third quarter sales were $73.3
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 26, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) intends to report financial results for the third quarter of 2004 prior to the Nasdaq market opening on Thursday, October 28, 2004. The Company will conduct a conference call to discuss the results on
HAWTHORNE, N.Y., Oct. 13, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. ("Taro") (Nasdaq:TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug
Alerts are e-mailed to you whenever certain new company information is posted to this site.
